/

Società

Da

Non verificato

Daiichi Sankyo

Di cosa scriviamo

FarmaceuticaIndustriaMedicina - VarieOncologiaSalute

81 comunicati stampa

Guarda tutti i comunicati

19/01/2026

Oncologia

Salute

Medicina - Varie

Scienza

Farmaceutica

Biotecnologia

Industria

ENHERTU® Plus Pertuzumab Type II Variation Application Validated in the EU as First-Line Treatment of Patients with HER2 Positive Metastatic Breast Cancer

Fonte

Emittente

1.00

0

13/01/2026

Scienza

Biotecnologia

Farmaceutica

Oncologia

Sanità

Salute

Medicina - Varie

Industria

TROPION-Lung17 TROP2 Biomarker Directed Phase 3 Trial of DATROWAY® Initiated in Patients with Previously Treated Advanced Nonsquamous Non-Small Cell Lung Cancer

Fonte

Emittente

1.00

0

07/01/2026

Oncologia

Salute

Sanità

Medicina - Varie

Farmaceutica

Biotecnologia

Mercato del lavoro

Industria

Daiichi Sankyo and GENESIS Pharma Enter Exclusive Agreement for VANFLYTA® Commercialization in Central and Eastern Europe

Fonte

Emittente

1.00

0

22/12/2025

Industria

Scienza

Biotecnologia

Farmaceutica

Oncologia

Sanità

Salute

Medicina - Varie

DESTINY-Endometrial02 Phase 3 Trial of ENHERTU® Initiated as Adjuvant Therapy in Patients with HER2 Expressing Endometrial Cancer

Fonte

Emittente

1.00

0

22/12/2025

Industria

Oncologia

Salute

Igiene alimentare

Biotecnologia

Medicina - Varie

Farmaceutica

ENHERTU® Granted Breakthrough Therapy Designation in the U.S. as Post-Neoadjuvant Therapy for Patients with HER2 Positive Early Breast Cancer

Fonte

Emittente

1.00

0

18/12/2025

Industria

Oncologia

Salute

Medicina - Varie

Sanità

Farmaceutica

Biotecnologia

DATROWAY® Type II Variation Application Validated in the EU as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who are Not Candidates for Immunotherapy

Fonte

Emittente

1.00

0

15/12/2025

Industria

Scienza

Farmaceutica

Oncologia

Vetrine/Shopping

Biotecnologia

Medicina - Varie

Salute

ENHERTU® Plus Pertuzumab Approved in the U.S. as First New Treatment in More Than a Decade for First-Line Treatment of Patients with HER2 Positive Metastatic Breast Cancer

Fonte

Emittente

1.00

0

09/12/2025

Industria

Biotecnologia

Salute

Farmaceutica

Oncologia

Scienza

Vetrine/Shopping

Medicina - Varie

DESTINY-Ovarian01 Phase 3 Trial of ENHERTU® Initiated as First-Line Maintenance Therapy in Patients with HER2 Expressing Advanced Ovarian Cancer

Fonte

Emittente

1.00

0

08/12/2025

Biotecnologia

Farmaceutica

Salute

Industria

Daiichi Sankyo Showcases Strength of Industry-Leading ADC Portfolio with Latest Research Updates from Five Landmark Breast Cancer Trials at SABCS

Fonte

Emittente

1.00

0

03/12/2025

Legge/Diritto

Oncologia

Salute

Sanità

Farmaceutica

Cardiologia

Biotecnologia

Federal Circuit Court of Appeals Vacates Infringement Judgment and Damages Award in Dispute between Daiichi Sankyo and Seagen

Fonte

Emittente

1.00

0

Seguaci

0

Compatibilità

0